South Korea-based regenerative medicine company PharmaResearch announced on Thursday the signing of a strategic partnership agreement with VIVACY, a France-based global medical aesthetics company, to distribute its medical device brand Rejuran in the European market.
VIVACY is involved in the European medical aesthetics industry, with subsidiaries and branch offices across key cities in Europe to support its commercial and marketing network.
Through this strategic partnership, PharmaResearch aims to combine VIVACY's distribution network and its own expertise in the market to accelerate its brand's entry and presence in Europe.
The agreement is valued at approximately EUR54.5m over five years, and spans 22 countries, including the major Western European markets (United Kingdom, Germany, France, Italy, and Spain).
PharmaResearch plans to start distributing in the key European countries before the end of the year, followed by a phased rollout across the region.
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
Covalon Technologies secures DTC eligibility to expand US investor access
Navamedic ASA secures final approvals for Flexilev in OraFID across Nordic markets
Oncopeptides partners with SD Pharma to expand Pepaxti access in Spain
Aptar launches bio-based nasal spray pump with Haleon's Otrivin brand
MAP Medical agrees distribution deal with Metrix-Secure
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Predictmedix AI launches mobile diabetes screening platform in India
Navamedic's medical device OraFID approved as primary package for a pharmaceutical product
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions
Immuno Cure and PharmaJet collaborate for novel HIV therapeutic DNA vaccine advancement